The WaferiXTM technology consists of a small wafer prepared by proprietary formulation using the freeze-drying process. The wafer is intended to be placed under the tongue, which subsequently dissolves within one minute, releasing the active compounds for rapid absorption in a time sensitive manner. The wafer administration is reported to be tolerable with no after-taste, leaving behind no residue or grittiness under the tongue hence preventing the urge to swallow.
The WaferiXTM technology provides a simple drug carrier matrix with millions of tiny amorphous holes to house (encapsulate) the active drug molecules in a cost-effective manner of delivering drugs which otherwise cannot be administered orally due to their poor oral absorption and/or extensive loss to the first pass hepatic metabolism. The only way to administer these drugs is by intravenous (“IV”) administration but sometimes the IV route may be impractical (e.g. in traumatic conditions like severe burns). There is also the issue of phobia of injections especially in children and some elderly in which case, the sublingual oral delivery of a pharmaceutical drug is more desirable. For health care workers, it will help prevent needle-stick injuries in compliance to occupational, health and safety practices. The rapid and superior absorption characteristics provide higher bioavailability and a potential to lower the administered dose and reduce the concurrent side effects. These benefits allow for the application of WaferiXTM in conditions where instantaneous therapeutic effect is desired, like acute or breakthrough pain as well as male erectile dysfunction.
WaferiXTM is a multiple platform drug carrier technology that was used to develop the world's first sublingual ketamine oral wafer, WafermineTM . We have also used WaferiXTM in our pharmaceutical products, to deliver active compounds like sildenafil citrate (WafesilTM ) and buprenorphine (BnoXTM ). In our nutraceuticals range, we have also applied WaferiXTM to WaferestTM to deliver melatonin, and to LumeniXTM to deliver glutathione. Our technology is easily adaptable to a vast number of other FDA approved drugs that require a faster delivery or reduction in the loss of drugs due to hepatic and gastrointestinal metabolism.